PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients
Open Access
- 9 November 2017
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 59 (6) , 922-928
Abstract
This study was designed to study the safety, biodistribution, radiation dosimetry of a gastrin-releasing peptide receptor (GRPR) antagonist positron emission tomography (PET) tracer 68Ga-RM26, to assess its clinical diagnostic value in prostate cancer patients, and to perform a direct comparison between GRPR antagonist 68Ga-RM26 and agonist 68Ga-BBN. Methods: Five healthy volunteers were enrolled to validate the safety of 68Ga-RM26 and calculate dosimetry. A total of 28 patients with prostate cancer (17 newly diagnosed and 11 post therapy) were recruited with written informed consent. All the cancer patients underwent PET/CT scans at 15-30 min after intravenous injection of 1.85 MBq (0.05 mCi) per kilogram body weight of 68Ga-RM26. Among them, 22 patients (11 newly diagnosed and 11 post therapy) accepted 68Ga-BBN PET/CT for comparison within 1 week. 99mTc-MDP bone scans were performed within 2 weeks for comparison. GRPR immunohistochemical staining of tumor samples was performed. Results: The administration of 68Ga-M26 was well tolerated by all subjects with no adverse symptoms being noticed or reported during the whole procedure and 2 weeks follow up. The total effective dose equivalent (EDE) and effective dose (ED) were 0.0912 ± 0.0140 and 0.0657 ± 0.0124 mSv/MBq, respectively. In the 17 patients with newly diagnosed prostate cancer, 68Ga-RM26 PET/CT showed positive prostate-confined findings in 15 tumors with SUVmax of 6.49 ± 2.37. In the 11 patients underwent prostatectomy or brachytherapy with/without androgen deprivation therapy (ADT), 68Ga-RM26 PET/CT detected 8 metastatic lymph nodes in three patients with SUVmax of 4.28 ± 1.25, and 21 bone lesions in 8 patients with SUVmax of 3.90 ± 3.07. Compared with 68Ga-RM26 PET/CT, GRPR agonist 68Ga-BBN PET/CT detected less primary lesions and lymph node metastases as well as lower tracer accumulation. There was a significant positive correlation between SUV derived from 68Ga-RM26 PET and the expression level of GRPR (P < 0.001). Conclusion: This study indicates the safety and significant efficiency of GRPR antagonist 68Ga-RM26. 68Ga-RM26 PET/CT would have remarkable value in detecting both primary prostate cancer and metastasis. 68Ga-RM26 is also expected to be better than GRPR agonist as an imaging marker to evaluate GRPR expression in prostate cancer.Keywords
This publication has 33 references indexed in Scilit:
- Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Furosemide diminishes 18F-fluoroethylcholine uptake in prostate cancer in vivoEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- ESUR prostate MR guidelines 2012European Radiology, 2012
- Profiling gastrin‐releasing peptide receptor in prostate tissues: Clinical implications and molecular correlatesThe Prostate, 2011
- EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reportingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- High expression of peptide receptors as a novel target in gastrointestinal stromal tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004